Neoplasms

Digestive System Diseases

Gland and Hormone Related Diseases

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Pancreatic Neoplasms

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Urinary Bladder Neoplasms

Pancreatic Cancer

Antineoplastic Agents

All Drugs and Chemicals

Anti-Arrhythmia Agents

Vasodilator Agents

Analgesics

Gemcitabine

Pembrolizumab

Paclitaxel

Docetaxel

Albumin-Bound Paclitaxel

Immunomodulating Agents

Adenosine

Tubulin Modulators

Antimitotic Agents

Antimetabolites

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

TTX-030 plus budigalimab (selected tumors evaluated in expansion)

TTX-030 plus budigalimab plus nab-paclitaxel + gemcitabine

TTX-030 plus nab-paclitaxel + gemcitabine

TTX-030, budigalimab and mFOLFOX6

TTX-030, budigalimab and docetaxel

TTX-030 and mFOLFOX6

TTX-030 and budigalimab

TTX-030, budigalimab, nab-paclitaxel and gemcitabine

TTX-030 and pembrolizumab

TTX-030, nab-paclitaxel and gemcitabine

Budigalimab and mFOLFOX6

This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response.

This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TTX-030 in combination with immunotherapy and/or standard chemotherapies.

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination With Pembrolizumab or Budigalimab and/or Chemotherapy in Subjects With Advanced Solid Tumors

Number of study subjects experiencing adverse events (AEs), dose-limiting toxicities, and serious adverse events (SAEs). Safety profile will be assessed through laboratory evaluations, vital signs, and physical examinations.

ORR is defined as the proportion of subjects with CR or PR

DoR will be defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.

DCR is defined as the proportion of subjects with CR, PR, or SD

PFS is measured from documentation of progression or death from any cause, whichever occurs first

Serum concentrations of TTX-030 will be tabulated

AbbVie

Trishula Therapeutics, Inc.

Spots Global Cancer Trial Database for budigalimab and mfolfox6